Sanofi-Aventis said it has acquired 84.6% of Genzyme's common stock and will allow Genzyme shareholders to tender the remaining shares between today and Thursday. The completion of the $20.1 billion offer will allow Sanofi to integrate the biotech firm with its business and gain access to rare disease treatment areas.

Full Story:

Related Summaries